Zyprexa news from FierceBiotech
NewsALSO NOTED: ASCO already churning out news; Lilly, FDA ironing out Zyprexa shot problems; and much more...
> Today marks the start of the annual ASCO. Here's a round-up of some of the news coming out of the conference. Read more...
Lilly readies Phase III Alzheimer's trial
Struggling to right itself after a long dry spell in new drug approvals, Eli Lilly is preparing to a launch a late-stage study of an experimental drug for Alzheimer's. LY450139 is expected to inhibit Read more...
ALSO NOTED: Analysts offer conflicting forecasts for Auxilium; test sheds light on cancer therapy; MAP touts new data; and much
> Two analysts assessed Auxilium Pharmaceuticals' chances in a late-stage study of Xiaflex and came up with radically different conclusions. Data is expected in the second quarter. Read more...
ALSO NOTED: Amgen analysts bearish; FDA hands Kyowa not-approvable letter; Valeant plans review; and much more...
> Oh, the curse of duplication. Schering-Plough embarked on a company-wide downsizing yesterday, eliminating hundreds of jobs in nearly all departments, including finance, research, information Read more...
Schering-Plough buoyed by asenapine data
Researchers say that Organon's asenapine was just as effective in controlling episodes of acute mania in two late-stage trials as Eli Lilly's Read more...
ALSO NOTED: Bavarian Nordic earns milestone payment; Cyclacel acquires Align Pharmaceuticals; and much more...
> Bavarian Nordic has earned a $50 million advanced payment for achieving milestones outlined in its contract to provide smallpox vaccine to the U.S. government. Read more...
Press Release: Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine in JapanPress Release: Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine in Japan Read more...SPOTLIGHT: Lilly settles Zyprexa claimsEli Lilly has settled another 18,000 claims generated by its controversial antipsychotic drug Zyprexa. Lilly says the settlement won't reduce fourth-quarter profits by more than $500 million. Report Lilly ignored Zyprexa safety data on weight, blood sugarThe New York Times reports that Eli Lilly initially ignored data gathered on clinical trials related to Zyprexa which showed that 16 percent of patients taking the schizophrenia drug gained more than 66 pounds. Instead, they focused on the results of a smaller group of trials that showed 30 percent of patients gaining 22 pounds. Initial data indicated that patients on Zyprexa were 3.5 times more likely to experience elevated blood sugar levels than volunteers taking a placebo. … Read more...Lilly hopes to nail Icos bid with sweetened offerEli Lilly has sweetened its offer for Seattle-based Icos by $200 million, raising its offer to $2.3 billion in hopes of damping down criticism that its original bid was too low. Icos investors are scheduled to consider the buyout offer--which was described as Lilly's last--on the day after Christmas. The offer raises Lilly's bid to $34 a share from $32. "We are confident that Icos shareholders will recognize the substantial value and the certainty that Lilly is offering," said … Read more... | Press ReleasesPRESS RELEASE: Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia Bristol Meyers Squibb/Otsuka Read more... |
Get more Zyprexa coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets